In 2021, the market for the Atrial Fibrillation Devices Industry was estimated to be worth US$ 3.2 billion, and by 2032, it is anticipated to be worth US$ 17.9 billion. With a market share of more than 59%, the ablation catheter segment dominates the global market under the product category. Over the forecast period (2022–2032), it is anticipated to increase at a CAGR of almost 18.3%.
Atrial fibrillation is a condition characterized by an erratic and extremely rapid heartbeat brought on by the rapid electrical discharge from the heart’s atria. The twitching of the atria brought on by these impulses is referred to as fibrillation. Atrial fibrillation limits the flow of blood from the atria to the ventricles, which increases the risk of clots and, ultimately, of stroke and heart failure.
Growing awareness of cardiac arrhythmias and their treatment will significantly contribute to the demand for atrial fibrillation devices. The two main catheter ablation approaches for pulmonary vein (PV) isolation are cryo balloon ablation and radiofrequency ablation, which are easier to use and are considered a low-risk procedure.
Request a Sample of this Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2214
Initiatives taken by various organization to create awareness and prevention amongst people has significantly increased the awareness regarding lifestyle modification and regular habits. For instance, the month of September is precisely donated for this disease, known as the National Atrial Fibrillation Awareness Month.
Traditionally, catheter-based ablation is used to treat patients with atrial fibrillation that have certain limitations in reducing the chance of complications after the procedure. Thus, the new line of treatment options such as the watchman device, FIRM ablation, and maze and thoracoscopic hybrid ablation are invented and well-performed, globally.
The focal impulse and rotor modulation (FIRM) ablation technique is used to more precisely locate the area of arrhythmia. Therefore, the increasing use of atrial fibrillation devices for these procedures will upsurge the growth of the atrial fibrillation devices market.
However, till now, only a few key players such as Biosense Webster, Inc., Abbott Laboratories, Medtronic Plc, and Boston Scientific Corporation are actively involved in the manufacturing of atrial fibrillation devices, which will create huge opportunities for other small as well as big manufacturers to enter the atrial fibrillation devices market.
Key Takeaways from Market Study
- In terms of product type, the ablation catheters segment accounted for the highest share of more than 59% in 2021.
- By end use, hospital segment dominates the atrial fibrillation devices market with an over 62% value share in 2021, owing to the increasing need for atrial fibrillation devices in critical care units for cardiac procedures.
- North America accounts for the highest share of 46.6% of the global atrial fibrillation devices market in 2021, due to the increased prevalence of atrial fibrillation rate in this region.
Contact our Market Research Specialist:
https://www.futuremarketinsights.com/ask-question/rep-gb-2214
“Increasing prevalence of atrial fibrillation and increased awareness among the public about the cardiac arrhythmias will boost the market over the forecast period,” says an analyst of Future Market Insights.
Market Competition
Prominent market players in the atrial fibrillation devices market are focusing on the development, approval and launch of new devices, to upsurge their product portfolio and expand their regional presence.
Additionally, manufacturers are focusing on forwarding integration to partner with wholesalers, distributors, and other channel partners to gain ownership over the value chain
- In March 2021, Medtronic plc, announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect which is a pulsed-field ablation (PFA) system, a novel technology that uses pulsed electric fields to treat atrial fibrillation (AF).
- On November 02, 2020, Abbott bagged the CE mark approval and Australian approval for its EnSite X EP System, a cardiac mapping system indicated for ablation therapy for abnormal heart rhythms.
Get Your Report Customize, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-2214
Key Companies Profiled:
- Biosense Webster, Inc
- Abbott Laboratories
- Medtronic Plc
- Boston Scientific Corporation
- GE Healthcare
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Japan Lifeline Co. Ltd.
- Stereotaxis, Inc.
- Microport Scientific Corporation
- AtriCure, Inc.
- Biotronik SE & Co. KG
- Acutus Medical Inc.
- Baylis Medical Company, Inc.
- EP Solutions
- Teleflex
- Merit Medical Systems Inc.
- Biomerics
Atrial Fibrillation Devices Market by Category
By Product:
- Laboratory Devices
- 3D Mapping Systems
- EP Recording Systems
- RF Ablation Systems
- ICE Systems
- Cardiac Stimulators
- Others
- Ablation Catheters
- Cryoablation
- RF Ablation
- Irrigated Tip RF
- Laser
- Diagnostic Catheters
- Conventional
- Advanced
- Ultrasound
- Access Devices
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/2214
By End-User:
- Hospitals
- Ambulatory Surgical Centers
- Cardiac Catheterization Laboratories
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
